Art. 107k Directive (EU) 2001/83

In forcesince 20 Jan 2011cited 9×
1.

Where the scope of the procedure, as determined in accordance with Article 107i(4), does not include any marketing authorisation granted in accordance with the centralised procedure provided for in Chapter 1 of Title II of Regulation (EC) No 726/2004, the coordination group shall, within 30 days of receipt of the recommendation of the Pharmacovigilance Risk Assessment Committee, consider the recommendation and reach a position on the maintenance, variation, suspension, revocation or refusal of the renewal of the marketing authorisation concerned, including a timetable for the implementation of the agreed position. Where an urgent adoption of the position is necessary, and on the basis of a proposal by its chairman, the coordination group may agree to a shorter deadline.

2.

If, within the coordination group, the Member States represented reach agreement on the action to be taken by consensus, the chairman shall record the agreement and send it to the marketing authorisation holder and the Member States. The Member States shall adopt necessary measures to maintain, vary, suspend, revoke or refuse renewal of the marketing authorisation concerned in accordance with the implementation timetable determined in the agreement.

In the event that a variation is agreed upon, the marketing authorisation holder shall submit to the national competent authorities an appropriate application for a variation, including an updated summary of product characteristics and package leaflet within the determined timetable for implementation.

If an agreement by consensus cannot be reached, the position of the majority of the Member States represented within the coordination group shall be forwarded to the Commission which shall apply the procedure laid down in Articles 33 and 34. However, by way of derogation from Article 34(1), the procedure referred to in Article 121(2) shall apply.

Where the agreement reached by the Member States represented within the coordination group or the position of the majority of the Member States represented within the coordination group differs from the recommendation of the Pharmacovigilance Risk Assessment Committee, the coordination group shall attach to the agreement or majority position a detailed explanation of the scientific grounds for the differences together with the recommendation.

3.

Where the scope of the procedure, as determined in accordance with Article 107i(4), includes at least one marketing authorisation granted in accordance with the centralised procedure provided for in Chapter 1 of Title II of Regulation (EC) No 726/2004, the Committee for Medicinal Products for Human Use shall, within 30 days of receipt of the recommendation of the Pharmacovigilance Risk Assessment Committee, consider the recommendation and adopt an opinion on the maintenance, variation, suspension, revocation or refusal of the renewal of the marketing authorisations concerned. Where an urgent adoption of the opinion is necessary, and on the basis of a proposal by its chairman, the Committee for Medicinal Products for Human Use may agree to a shorter deadline.

Where the opinion of the Committee for Medicinal Products for Human Use differs from the recommendation of the Pharmacovigilance Risk Assessment Committee, the Committee for Medicinal Products for Human Use shall attach to its opinion a detailed explanation of the scientific grounds for the differences together with the recommendation.

4.

On the basis of the opinion of the Committee for Medicinal Products for Human Use referred to in paragraph 3, the Commission shall:

(a)

adopt a decision addressed to the Member States concerning the measures to be taken in respect of marketing authorisations that are granted by the Member States and that are subject to the procedure provided for in this section; and

(b)

where the opinion is that regulatory action is necessary, adopt a decision to vary, suspend, revoke or refuse renewal of the marketing authorisations granted in accordance with Regulation (EC) No 726/2004 and subject to the procedure provided for in this section.

Articles 33 and 34 of this Directive shall apply to the adoption of the decision referred to in point (a) of the first subparagraph of this paragraph and to its implementation by the Member States. However, by way of derogation from Article 34(1) of this Directive, the procedure referred to in Article 121(2) thereof shall apply.

Article 10 of Regulation (EC) No 726/2004 shall apply to the decision referred to in point (b) of the first subparagraph of this paragraph. However, by way of derogation from Article 10(2) of that Regulation, the procedure referred to in Article 87(2) thereof shall apply. Where the Commission adopts such decision, it may also adopt a decision addressed to the Member States pursuant to Article 127a of this Directive.

  • Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…20266267Law

    … 107j odst. 2 směrnice 2001/83/ES. 9. Odchylně od odstavců 1 až 7 tohoto článku, pokud se postup podle článků 31 nebo 107i až 107k směrnice 2001/83/ES týká skupiny léčivých přípravků nebo terapeutické skupiny, vztahuje …

  • Regulation (EU) 2019/51Law

    … for tjenester, der ydes af koordinationsgruppen i forbindelse med udførelsen af dens opgaver i overensstemmelse med artikel 107c, 107e, 107g, 107k og 107q i direktiv 2001/83/EF d) afgifter for andre tjenester, som agenturet yder e) …

  • Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 Decembe…1Law

    … Odchylně od odstavců 1 až 7 tohoto článku, pokud se postup podle článků 31 nebo 107i až 107k směrnice 2001/83/ES týká skupiny léčivých přípravků nebo terapeutické skupiny, vztahuje se na léčivé přípravky, které …

  • Regulation (EU) 2024/568Law

    … 31 odst. 1 druhého pododstavce, čl. 31 odst. 2 a článků 107i, 107j a 107k směrnice 2001/83/ES nebo podle čl. 20 odst. 8 nařízení (ES) č. 726/2004 se uplatní tyto poplatky: 6.7.1. poplatek ve výši 219900 EUR, pokud posouzení …

  • Gesetz über den Verkehr mit Arzneimitteln3063eLaw

    … Zulassung, den Widerruf, die Rücknahme oder das Ruhen der Zulassung auf einer Einigung der Koordinierungsgruppe nach Artikel 107g, 107k oder Artikel 107q der Richtlinie 2001/83/EG beruht. Ein Vorverfahren nach § 68 der …

  • Judgment of the Court (First Chamber) of 21 November 2018. Novartis Farma SpA v Agenzia Italiana del Farmaco (AIFA) and Others.Decision

    … 2001/83/ES; protokoly a veřejné souhrny poregistračních studií bezpečnosti […] zahájení postupu podle článků 107i až 107k směrnice 2001/83/ES […] závěry hodnocení, doporučení, stanoviska, schválení a rozhodnutí …

    21 Nov 2018 · 62017CJ0029

  • Judgment of the Court (Third Chamber) of 25 November 2021. Delfarma Sp. z o.o. v Prezes Urzędu Rejestracji Produktów Leczniczych, Wyrobów MeDecision

    … Články 107i, 107j a 107k směrnice 2001/83 totiž zavedly postup pro naléhavé záležitosti, díky němuž mohou být všechny členské státy informovány v případě, kdy léčivý přípravek způsobuje takové problémy, že jsou …

    25 Nov 2021 · 62020CJ0488

  • Regulation (EU) 2019/5 of the European Parliament and of the Council of 11 December 2018…1Law

    … 2019/6; and for services provided by the coordination group as regards the fulfilment of its tasks in accordance with Articles 107c, 107e, 107g, 107k and 107q of Directive 2001/83/EC; (d) charges for other services provided by the …

  • Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 Decembe…1Law

    … By way of derogation from paragraphs 1 to 7 of this Article, where a procedure under Article 31 or Articles 107i to 107k of Directive 2001/83/EC concerns a range of medicinal products or a therapeutic class, medicinal products that are …